Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies

8 Aug 2023

Abstract excerpt

The greater efficacy of DNA-damaging drugs for pancreatic adenocarcinoma (PDAC) relies on targeting cancer-specific vulnerabilities while sparing normal organs and tissues due to their inherent toxicities. We tested LP-184, a novel acylfulvene analog, for its activity in preclinical models of PDAC carrying mutations in the DNA damage repair (DDR) pathways. Cytotoxicity of LP-184 is solely dependent on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37552607
DOI: 10.1158/1535-7163.mct-22-0818

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair DeficienciesPMID 37552607Read ↗

DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical PerspectivesSemantic proximity Read ↗

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.Semantic proximity Read ↗

Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent TumorsSemantic proximity Read ↗

Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidenceSemantic proximity Read ↗

Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug RepurposingSemantic proximity Read ↗

Inhibition of Non-Homologous End Joining Repair Impairs Pancreatic Cancer Growth and Enhances Radiation ResponseSemantic proximity Read ↗

Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancerSemantic proximity Read ↗

In vivo CRISPR screening identifies geranylgeranyl diphosphate as a pancreatic cancer tumor growth dependencySemantic proximity Read ↗

Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)–Deficient Pancreatic Cancer CellsSemantic proximity Read ↗

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with OlaparibSemantic proximity Read ↗

Therapeutic Targeting of Oncogene-induced Transcription-Replication Conflicts in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.